FDA Advisory Committee Unanimously Recommends Reintroduction Of Biogen Idec, Inc. (Massachusetts) And Elan Corporation PLC’s TYSABRI(R) For The Treatment of Relapsing Forms Of Multiple Sclerosis; Shares Jump

GAITHERSBURG, Md.--(BUSINESS WIRE)--March 8, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend reintroduction of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS).